Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled liposomal cyclosporin A for moderate COVID-19 pneumonia (proof-of-concept Phase II)
2020-003505-58Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Nov 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine in coronavirus pneumonia and coronavirus disease 2019 (COVID-19), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Safety and treatment response at 7 days. Started Nov 2020; status: completed.
02
Drugs
cyclosporine
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003505-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003505-58.